Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase...

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Matrix metalloproteinases (MMPs) are crucial enzymes regulated by tissue inhibitors of metalloproteinases (TIMPs).
• Four TIMPs are known, with molecular weights between 20,000 and 29,000.
• Understanding MMP regulation is vital in various biological processes and diseases.

Purpose of the Study:

• To identify and characterize novel metalloproteinase inhibitors.
• To investigate the potential role of these inhibitors in human brain tumor cells.
• To determine if the novel inhibitor is related to known TIMPs.

Main Methods:

• Reverse zymography was used to detect metalloproteinase inhibitor activity.
• Affinity and ion exchange chromatography were employed for inhibitor isolation.
• N-terminal sequencing and comparison with known protein domains were performed.

Main Results:

• A novel inhibitor with an apparent molecular weight of 16,500 was detected in human brain tumor cell conditioned medium.
• Antibodies against known TIMPs did not react with the inhibitor.
• N-terminal sequencing revealed homology to procollagen C-terminal proteinase enhancer (PCPE), leading to the name CT-PCPE.
• CT-PCPE contains six cysteine residues and its activity is abolished by reduction and alkylation, similar to TIMPs.
• Purified CT-PCPE showed weak inhibition of MMP-2 compared to TIMP-2.

Conclusions:

• CT-PCPE is a novel metalloproteinase inhibitor isolated from human brain tumor cells.
• It is structurally distinct from known TIMPs but shares some functional characteristics.
• MMPs may not be the primary physiological targets of CT-PCPE.
• CT-PCPE may represent a new class of metalloproteinase inhibitors with potential implications in cancer biology.